INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for many hematological malignancies, 1 but outcomes depend on multiple risk factors. Among these, disease type and status at the time of transplant are crucial elements. The disease risk index (DRI) is a risk score based on these factors that assignment of patients to different prognostic groups. 2 Recently, this score was refined ('refined DRI') in a cohort of 413 000 patients. 3 Stratification into four groups of low-, intermediate-, high-and very-high-risk predicted 2-year overall survival (OS) better than stratification using the original DRI. This score has not yet been evaluated for partial in vitro T-cell-depleted grafts (TDEP) but may be a valuable tool to compare outcomes of different HSCT protocols. In the Geneva Stem Cell Transplant Center, we use TDEP mainly for patients in CR at the time of transplant. Donor lymphocytes mediate the GvL, [4] [5] [6] but alloreactive T-cells can also trigger severe GvHD. 7 However, the use of TDEP for selected patients can decrease GvHD without impairing survival or increasing the risk of relapse. 8 In this study, we determined initially the prognostic value of the refined DRI for patients receiving partial TDEP and non-TDEP. We then used the refined DRI to stratify patients and compare outcomes between these two patient groups.
PATIENTS AND METHODS Patients
This retrospective study comprised all consecutive adult patients who underwent allogeneic HSCT for hematological malignancies between January 1998 and December 2013 at Geneva's University Hospitals, Geneva, Switzerland. Only data related to the first HSCT were analyzed. All data on patient characteristics, disease and status were extracted retrospectively from the hospital medical records.
Transplantation
Myeloablative conditioning (MAC) usually consisted of cyclophosphamide (120 mg/kg) in combination with total body irradiation (10-12 Gy) or busulfan (16 mg/kg oral or 12.8 mg/kg intravenously) and reduced intensity conditioning (RIC), including fludarabine (120 mg/m 2 ) with low-dose busulfan (8 mg/kg oral or 6.4 mg/kg intravenously) or melphalan (140 mg/m 2 ). In general, antithymocyte globulin (ATG) (Thymoglobulin 7.5 mg/kg or ATG-Fresenius 25 mg/kg) was part of conditioning for all patients treated with RIC, for patients allografted with MAC and an unrelated donor and for all CML patients allografted with MAC and TDEP. TDEP patients received methylprednisolone (1000 mg/m 2 ). Partial in vitro T-cell depletion was performed using alemtuzumab (Campath (Genzyme Corporation, Cambridge, MA, USA)) 'in the bag'. 9, 10 TDEPs were given on day +0 followed by an add-back (usually 100 × 10 6 donor T-cells/kg) on day +1. RIC patients received incremental doses (starting with 5 × 10 5 CD3/kg for an unrelated donor and 1 × 10 6 /kg for a related donor) of donor lymphocyte infusion (DLI) from day +100 in the absence of GvHD. Incremental doses of DLI (0.5-log increase from 5 × 10 5 to 1 × 10 6 CD3/kg, then 1-log increase at each dose) were administered every 8 weeks until a maximum dose of 5 × 10 7 CD3/kg or development of GvHD. MAC patients did not receive DLI as part of our treatment protocol. In addition, patients with decreasing donor chimerism or in relapse also received DLI.
GvHD prophylaxis after MAC usually consisted of cyclosporine (target serum level between 200 and 300 ng/ml for non-TDEP and between 150 and 200 ng/ml for TDEP) and methotrexate (administered at days +1, +3, +6). After RIC, patients received cyclosporine (target serum level between 200 and 300 ng/ml for non-TDEP and between 150 and 200 ng/ml for TDEP) and mycophenolate mofetil (1000 mg twice daily for non-TDEP and 500 mg twice daily for TDEP for 28 days).
Definitions
We used the same definitions as Armand et al. 3, 11, 12 for disease stage classification, cytogenetic classification and to assign patients to the four DRI groups. 3 When cytogenetic data were not available for AML and myelodysplastic syndromes (MDS), patients were classified as intermediate risk. Unrelated donors were considered to be (mis)matched donors after HLA typing for HLA-A, -B, -C, -DRB1 and DQB1 alleles.
Chimerism status was assessed on peripheral blood samples using polymorphic short tandem repeats on informative loci. Chimerism was determined in granulocytes and mononuclear cells after separation by density gradient centrifugation. Complete donor chimerism (CC) was defined as ⩾ 97% donor chimerism in granulocytes and mononuclear cells.
Outcomes
The primary outcome was the comparison of OS between TDEP (defined as those who received a partial in vitro TDEP, irrespective of the use of ATG as part of the conditioning regimen) and non-TDEP patients when stratified by the refined DRI. The very-high-risk group of TDEP patients (only four individuals) was excluded from the statistical analysis. Secondary outcomes were: (1) the comparison of PFS between TDEP and non-TDEP patients; (2) 2-and 5-year OS, PFS, relapse incidence (RI) and non-relapse mortality (NRM) for each refined DRI group for the whole cohort and specifically for TDEP and non-TDEP patients; (3) impact of the refined DRI on full chimerism at 30 and 90 days after HSCT; and (4) impact of TDEP on the incidence of acute and chronic GvHD.
Validation of the refined DRI Before using the refined DRI to compare TDEP and non-TDEP, the score was validated in our cohort; each patient was first stratified into his/her own risk group (low, intermediate, high, very high) according to Armand et al. 3 Then we analyzed whether the estimated OS using the Kaplan-Meier method was significantly different for each risk group using log-rank test. A P-value o 0.05 was considered statistically significant, thus validating the refined DRI for our patients.
Statistics
Patient characteristics were reported descriptively. Categorical variables were expressed as proportions and continuous variables as median and range. OS and PFS were estimated using the Kaplan-Meier method. 13 Cumulative incidence estimates of RI, NRM and GvHD were calculated with death from other causes or relapses defined as competitive events by the Fine and Gray method.
14 The log-rank test was used to compare outcome probabilities. A Cox regression model was performed for OS, PFS, NRM and GvHD to identify associations with a donor-recipient sex combination, CMV donor-recipient status, donor type, refined DRI, T-cell depletion, source of stem cells, conditioning regimen, ATG use and time from diagnosis to transplantation. A two-sided P-value o0.05 was considered significant. The proportional assumption for each variable was assessed by the analysis of Schoenfeld residuals (P-value 40.05). We used SPSS version 21.0 (IBM Corp. Armonk, NY, USA) and R version 3.0.1 (Comprehensive R Archive Network (CRAN) project (http://cran.us.r-project.org)) for all statistical analyses.
RESULTS

Patients
We included 428 patients in the study; 170 (40%) were female. Median age was 48 years (range: 18-70). Two hundred and sixty-five (62%) patients received TDEPs. Median follow-up was 4.2 years (range: 0-15). Baseline characteristics and stratification according to the refined DRI are summarized in Table 1 .
Validation of the refined DRI and its implementation to compare outcomes of TDEP and non-TDEP patients For the whole cohort, 64 patients were stratified as low risk, 245 as intermediate risk, 98 as high risk and 21 as very high risk. A comparison of the estimated OS between risk groups by the log-rank test was statistically significant (P o0.001), thus validating the refined DRI for our patients. Similar results were obtained for TDEP and non-TDEP patients. The estimated OS using the Kaplan-Meier method is presented in Figure 1 .
To study the impact of patient selection on the composition of the TDEP and non-TDEP groups, we compared several patient and HSCT characteristics not included in the DRI for each refined DRI risk group, such as age at transplant, Karnofsky performance score and the European Blood and Marrow Transplantation (EBMT) risk score. We found no statistical difference in median age and the Karnofsky performance score between TDEP vs non-TDEP patients. The median EBMT score was similar for the low-, high-and very-high-risk group but differed for the intermediate-risk group (median EBMT score of 2 for TDEP, 3 for non-TDEP; P = 0.02).
After stratification according to the refined DRI, we compared OS and PFS between TDEP and non-TDEP patients. OS for TDEP and non-TDEP in low-, intermediate-and high-risk groups was similar (Figure 2 ). Likewise, there was no statistical difference in PFS between TDEP and non-TDEP patients ( Figure 3 ). Impact of refined DRI on OS, PFS, RI, NRM and chimerism Two-and 5-year OS for the whole cohort according to the refined DRI was 56.1% (95% confidence interval (CI): 51.1-61.1) and 46.8% (95% CI: 41.4-52.2), respectively, for TDEP patients, 62.3% (95% CI: 56.1-68.5) and 51.6% (95% CI: 45-58.2), respectively, and for non-TDEP patients, 44.7% (95% CI: 35.8-53.5) and 38.7% (95% CI: 29.7-47.7), respectively ( Table 2 ). The impact of the refined DRI on OS was confirmed by multivariate analysis (Table 3) . Of note, univariate analysis showed that the refined DRI was also prognostic for 2-and 5-year PFS and RI (P o0.001) for the whole cohort and for TDEP and non-TDEP patients (Table 2) , and this finding was confirmed by multivariate analysis (Supplementary Table S1 ). By contrast, univariate analysis did not show any significant difference in NRM according to the refined DRI ( Abbreviations: AP = accelerated phase; BC = blast crisis; BM = bone marrow; CB = cord blood; CP = chronic phase; CSA = cyclosporine; CST = corticosteroids; DLI = donor lymphocyte infusion; DRI = disease risk index; EBMT = European Blood and Marrow Transplantation; HL = Hodgkin lymphoma; MAC = myeloablative conditioning; MCL = mantle cell lymphoma; MDS = myelodysplasic syndrome; MM = multiple myeloma; MMD = mismatched donor; MMF = mycophenolate mofetil; MPN = myeloproliferative neoplasms; MRD = matched related donor; MTX = methotrexate; MUD = matched unrelated donor; Neg = negative; NHL = non-Hodgkin lymphoma; Pos = positive; RIC = reduced intensity conditioning; TDEP = T-cell-depleted graft.
Outcome of TDEP and non-TDEP patients using the DRI Y Beauverd et al achieving CC at 30 and 90 days was similar to results for the whole cohort and the non-TDEP patients.
Impact of TDEP on GvHD The 1-year incidence of acute GvHD (aGvHD) grades II-IV in TDEP patients (19.5% (95% CI: 14.9-24.6)) was significantly lower than in non-TDEP (49.3% (95% CI: 40.9-57.0); P o 0.0001). Similarly, the 1-year incidence of aGvHD grades III-IV was also significantly lower in TDEP patients (0.4% (95% CI: 0-1.2) vs 4.5% (95% CI: 1.1-7.9) for non-TDEP; Po 0.001) and was confirmed in multivariate analysis (Supplementary Table S2 2), P = 0.1, respectively).
DISCUSSION
The DRI was recently refined in a large cohort of 413 000 patients but was not yet confirmed for patients transplanted with TDEPs. In this retrospective study, we have validated the refined DRI by applying it to a cohort of 428 consecutive patients transplanted for hematological malignancies, including 265 patients (62%) allografted with TDEPs. As we were able to validate the refined DRI in TDEP as well as in non-TDEP patients, we used this tool to compare TDEP and non-TDEP patient outcome; no difference was observed for OS. Interestingly, there was also no difference in PFS between TDEP and non-TDEP, thus indicating that there was no excess of relapse hampering PFS for TDEP patients. In addition, TDEP patients suffered from less aGvHD, which would argue in favor of TDEP for selected patients. Outcome of TDEP and non-TDEP patients using the DRI Y Beauverd et al
In addition to being prognostic for 2-year OS, we also demonstrated that refined DRI is prognostic for PFS and RI. These results are not surprising as the disease type and burden at transplant are strongly associated with relapse. 2, 3, 8 Determinants of NRM are multiple and include patient characteristics (co-morbidities, 15 age at transplant 16 ), transplant characteristics (time to transplant, 16 recipient/donor mismatch, 16 recipient/donor sex combination 16 and disease status 16 ) and complications (GvHD 17 ). As disease status is the only one determinant of NRM, it was logical to find that the refined DRI was not prognostic for NRM. Not surprisingly, the proportion of CC (for granulocytes and mononuclear cells) was lower for TDEP than for non-TDEP patients at 30 and 90 days. However, mixed chimerism was due to the mononuclear fraction that has recently been shown not to be associated with worse outcome (OS and RI) in contrast with mixed chimerism for granulocytes. 18 Our study has some limitations. Patients were not randomly assigned to transplantation protocols and thus we cannot exclude selection bias with more patients with favorable prognostics in the TDEP group. To investigate whether such a bias could be demonstrated, we have compared other factors predictive of outcome for patients allocated in each refined DRI group (TDEP vs non-TDEP), such as the EBMT score, 16 Karnofsky performance status 19 and age at transplant. However, we did not find any statistically significant differences between the groups, with the exception of the intermediate-risk group that had different EBMT scores. The retrospective design and the long duration of our study may be also a limitation as supportive care and treatment with antibiotics have improved during this period, including survival after HSCT. 20, 21 In conclusion, our trial has validated the refined DRI for TDEP and non-TDEP patients. In addition to its interest as a risk score to stratify patients and help physicians to estimate the risk-benefit ratio of allogeneic HSCT, the refined DRI is a valuable tool to compare HSCT protocol and strategies. TDEP may be a reasonable strategy when patients are selected based on solid criteria, with the advantage that it seems not to impact on strong outcomes such as OS and PFS, and reduces aGvHD. Abbreviations: ATG = antithymocyte globulin; BM = bone marrow; CB = cord blood; CI = confidence interval; DRI = disease risk index; HR = hazard ratio; MAC = Myeloablative conditioning; MMD = mismatched donor; MRD = matched related donor MUD = matched unrelated donor; RIC = reduced intensity conditioning; TDEP = T-cell-depleted graft.
Outcome of TDEP and non-TDEP patients using the DRI Y Beauverd et al
